Navigation Links
IP-K extends research deal with Novartis Institute for Tropical Diseases
Date:12/2/2010

Dec. 03, 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) has signed an agreements to continue to mine the chemical compound collection of Novartis Institute for Tropical Diseases (NITD) of Singapore for new drug candidates.

IP-K's PhenomicScreen is a high-throughput, high-content visual screening platform that is ideally suited to identifying lead compounds. Over the past year, PhenomicScreen has been used to search for promising drugs within NITD's chemical compound collection. That deal has now been extended by two years to allow a further exploration of their chemical library.

Dr. Pablo Bifani, Project Team Head at NITD, welcomed his institute's new contract, noting that "The scientific approach we are taking with IP-K is greatly facilitating the selection of candidate compounds for further drug development."

IP-K's Dr. Jonathan Cechetto describes the advantages of PhenomicScreen as being that "The process selects novel targets, and only those which are functionally significant in the disease process". Dr. Priscille Brodin of IP-K adds that "The phenotypic approach does not rely on a predefined target, but rather simultaneously selects both chemical compounds and an unknown cellular target solely by the clearly discernible effect on the disease model".

Center Director of Core Technologies of Institut Pasteur Korea Dr. Veronica Soloveva said that "We are proud to be working with NITD in the fight against infectious diseases". Soloveva is satisfied that the agreement is a vindication of the institute's innovative approach to drug discovery. "Our PhenomicScreen technology is proven to increase the accuracy and speed of drug discovery," she says.


'/>"/>

Contact: Jean Kim
babunn@ip-korea.org
82-318-018-8041
Institut Pasteur Korea
Source:Eurekalert

Page: 1

Related biology news :

1. GenWay Biotech extends the You Test You program overseas
2. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
3. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
4. $5.1 million Army-Md. alliance speeds university research to market
5. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
6. Researchers describe first functioning lipidome of mouse macrophage
7. U of M researcher helps unlock 30 new genes responsible for early onset puberty
8. Stroke research takes 2 steps forward
9. Researchers find link between sugar, diabetes and aggression
10. Arjun Deb awarded Louis N. and Arnold M. Katz Basic Science Research Prize
11. Snakes on a rope: Researchers take a unique look at the climbing abilities of boa constrictors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
Breaking Biology Technology: